Mesenchymal stem cell therapy for severe COVID-19
  • 1.

    WHO. Coronavirus disease (COVID-2019) situation reports, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (2020).

  • 2.

    Gupta, A. et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 26, 1017–1032 (2020).

    CAS  PubMed  Article  Google Scholar 

  • 3.

    Petersen, E. et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect. Dis. 20, e238–e244 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 4.

    Richardson, S. et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 323, 2052–2059 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 5.

    Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369, eabc8511 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 6.

    Kuri-Cervantes, L. et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci. Immunol. 5, eabd7114 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 7.

    Song, J.-W. et al. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat. Commun. 11, 3410 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 8.

    Vabret, N. et al. Immunology of COVID-19: current state of the science. Immunity 52, 910–941 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 9.

    Horby, P. et al. Dexamethasone in Hospitalized Patients with . N. Engl. J. Med. 384, 693–704 (2021).

    CAS  PubMed  Article  Google Scholar 

  • 10.

    Li, L. et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: a randomized clinical trial. JAMA 324, 460–470 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 11.

    Salama, C. et al. Tocilizumab in Patients Hospitalized with Pneumonia. N. Engl. J. Med. 384, 20–30 (2021).

    CAS  PubMed  Article  Google Scholar 

  • 12.

    Zhou, T. et al. Clinical Efficacy and Safety of Mesenchymal Stem Cells for Systemic Lupus Erythematosus. Stem Cells Int. 2020, 6518508 (2020).

    PubMed  PubMed Central  Google Scholar 

  • 13.

    Hashmi, S. et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 3, e45–e52 (2016).

    PubMed  Article  Google Scholar 

  • 14.

    Chan, M. C. W. et al. Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo. Proc. Natl. Acad. Sci. USA 113, 3621–3626 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 15.

    Chen, J. et al. Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: a Hint for COVID-19 Treatment. Eng. (Beijing, China) 6, 1153–1161 (2020).

    CAS  Google Scholar 

  • 16.

    Matthay, M. A. et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir. Med. 7, 154–162 (2019).

    PubMed  Article  Google Scholar 

  • 17.

    Simonson, O. E. et al. In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome. Stem Cells Transl. Med. 4, 1199–1213 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 18.

    Wilson, J. G. et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir. Med. 3, 24–32 (2015).

    PubMed  Article  PubMed Central  Google Scholar 

  • 19.

    Zheng, G. et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir. Res. 15, 39 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  • 20.

    Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 8, 420–422 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 21.

    BMJ (Clin. Res. Ed.). 371, m3862 (2020).

    Google Scholar 

  • 22.

    Pei, G. et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. J. Am. Soc. Nephrol. 31, 1157–1165 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 23.

    Puelles, V. G. et al. Multiorgan and Renal Tropism of SARS-CoV-2. N. Engl. J. Med. 383, 590–592 (2020).

    PubMed  Article  Google Scholar 

  • 24.

    Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet (Lond. Engl.) 395, 1417–1418 (2020).

    CAS  Article  Google Scholar 

  • 25.

    Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 26.

    Tan, M. et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology 160, 261–268 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 27.

    Zhang, J.-Y. et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat. Immunol. 21, 1107–1118 (2020).

    CAS  PubMed  Article  Google Scholar 

  • 28.

    Front. Immunol. 11, 1049 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 29.

    Ogega, C. O. et al. Durable SARS-CoV-2 B cell immunity after mild or severe disease. J. Clin. Investig. 131, e145516 (2021).

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  • 30.

    Cell Stem Cell 22, 824–833 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 31.

    Pittenger, M. F. et al. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Med. 4, 22 (2019).

    Article  CAS  Google Scholar 

  • 32.

    Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Sci. (N. Y., N. Y.) 284, 143–147 (1999).

    CAS  Article  Google Scholar 

  • 33.

    J. Clin. Med. 8, 1025 (2019).

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  • 34.

    Zumla, A. et al. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancingongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy – achieving global consensus and visibility forcellular host-directed therapies. Int. J. Infect. Dis: Off. Publication Int. Soc. Infect. Dis. 96, 431–439 (2020).

    CAS  Article  Google Scholar 

  • 35.

    Wu, J. et al. Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs. Cell Prolif. 53, e12944 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  • 36.

    Leng, Z. et al. Transplantation of ACE2 Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 11, 216–228 (2020).

    PubMed  PubMed Central  Article  Google Scholar 

  • 37.

    Tang, L. et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front. Med. 14, 664–673 (2020).

    PubMed  Article  Google Scholar 

  • 38.

    Meng, F. et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct. Target. Ther. 5, 172 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 39.

    Hashemian, S.-M. R. et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem cell Res. Ther. 12, 91 (2021).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 40.

    Sengupta, V. et al. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 29, 747–754 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 41.

    Chen, X. et al. Mesenchymal stem cell therapy in severe COVID-19: a retrospective study of short-term treatment efficacy and side effects. J. Infect. 81, 647–679 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 42.

    Peng, H. et al. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report. Stem Cell Res. Ther. 11, 291 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 43.

    Liang, B. et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine 99, e21429 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 44.

    Sanchez-Guijo, F. et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine 25, 100454 (2020).

    PubMed  PubMed Central  Article  Google Scholar 

  • 45.

    Häberle, H. et al. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS. J. Inten. Care Med. 36, 681–688 (2021).

    Article  Google Scholar 

  • 46.

    Shu, L. et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res. Ther. 11, 361 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 47.

    Shi, L. et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct. Target. Ther. 6, 58 (2021).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  • 48.

    Lanzoni, G. et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem cells Transl. Med. 10, 660–673 (2021).

    PubMed  PubMed Central  Article  Google Scholar 

  • 49.

    US-FDA. https://www.fda.gov/vaccines-blood-biologics/biologics-research-projects/tissue-advanced-therapies-research

  • 50.

    Nat. Med. 25, 1037–1044 (2019).

    CAS  PubMed  Article  Google Scholar 

  • Read original article here.